FOURIER (TIMI 59) was a double-blind, randomized, placebo-controlled, multicenter study assessing the Impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease. EBBINGHAUS was a cognitive study of patients enrolled in the FOURIER trial.
MAIN RESULTS:
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

N Engl J Med. 2017 May 4;376(18):1713-1722.
MAIN RESULTS PRESENTATIONS
FOURIER Main Results (Sabatine, ACC 2017)
EBBINGHAUS Main Results (Giugliano, ACC 2017)
PRESENTATIONS
Maximum Intensity Statin (Sabatine, NLA 2017)
Achieved LDL-C (Giugliano, ESC 2017)
Stroke (Pederson, ESC 2017)
Diabetes (Sabatine, EASD 2017)
PAD (Bonaca, AHA 2017)
MI Subgroup (Sabatine, AHA 2017)
Total Events (Murphy, AHA 2017)
MI Size and Type (Wiviott, AHA 2017)
Risk Score (Bohula, AHA 2017)
Variability in Evolocumab (Qamar, ACC 2018)
Inflammatory and Cholestrol Risk (Bohula, ACC 2018)
Martin Hopkins LDL-C (Martin, NLA 2018)
Lp(a) in FOURIER (O’Donoghue, EAS 2018)
Age and Sex (Sever, ESC 2018)
FOURIER Cognition Poster (Gencer, AHA 2019)
FOURIER Genetics (Marston, AHA 2019)
FOURIER Recent MI Poster (Gencer, AHA 2019)
Performance Of A Novel Genetic Risk Score To Identify Risk Of VTE In Patients With Cardiometabolic Disease (Marston, ACC 2020)
PCSK9 Inhibition And Aortic Stenosis In The FOURIER Trial (Bergmark, ACC 2020)
Efficacy of Lowering Low-Density Lipoprotein Cholesterol in Older Patients (Gencer, AHA 2020)
Relationship Between Baseline LDL-C and %LDL-C Reduction with Evolocumab in the FOURIER Trial (Marcusa, AHA 2020)
Reduction with Evolocumab in Complex Coronary Revascularization (Oyama, AHA 2020)
A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients with Cardiometabolic Disease (Patel, AHA 2020)
Cardiovascular Outcomes in Patients with Established Atherosclerosis and LDLR Loss of Function (Marston, AHA 2020)
Combining High-Sensitivity Troponin with the AHA/ACC Cholesterol Guidelines To Guide Evolocumab Therapy (Marston, AHA 2020)
Effects of Evolocumab in Patients with Prior Percutaneous Coronary Intervention (Furtado, AHA 2020)
Biomarker prediction of major coronary events and complex revascularization procedures in patients with stable atherosclerosis (Fagundes, Jr., ACC 2021)
Acute arterial events across all vascular territories in the FOURIER trial (Oyama, ESC 2021)
Cardiovascular Benefit of Lowering LDL-C Below ~1 mmol per L (40 mg per dl) (Marston, ESC 2021)
Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease (Garfinkel, AHA 2021)
Clinical Safety Outcomes in Relation to Lipoprotein(a) Concentration. Insights from the FOURIER trial (Gencer, AHA 2021)
ApoB-containing Lipoproteins and Risk of Myocardial Infarction. Distinguishing between Particle Concentration, Type, and Content (Marston, AHA 2021)
A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease (Patel, AHA 2021)
Assessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus (Berg, ACC 2022)
Development of a Novel Polygenic Risk Score to Predict Risk of Aortic Stenosis Events (Small, AHA 2022)
Type 2 Diabetes Mellitus Polygenic Score Predicts New Onset Diabetes in Patients With Established Atherosclerotic Cardiovascular Disease-A FOURIER Sub-Study (Moura, AHA 2022)
Cardiovascular Benefit of Lowering LDL-C Below 40 mg per dl (Marston, AHA 2022)
Association Between Achieved LDL-Cholesterol and Long-term Cardiovascular and Safety Outcomes – An Analysis of the FOURIER and FOURIER-OLE Studies (Gaba, AHA 2022)
Reduction in Total CV Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the Combined FOURIER and FOURIER OLE Studies (Murphy, ACC 2023)
Genetically Mediated Vascular Endothelial Cell Dysfunction and Its Dependence on Serum LDL-C Levels for the Development of Coronary Artery Atherosclerosis: Insights from the UK Biobank and FOURIER Trial (Marston, ACC 2023)
Risk Of Kidney Disease Progression And Efficacy Of SGLT2 Inhibition In Patients With Type 2 Diabetes Mellitus (Moura, ACC 2023)
Lipoprotein(a) and the risk of Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease (Bonaca, ESC 2023)
OTHER PUBLICATIONS
Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 Aug 17;377(7):633-643.
Myocardial Infarction and Evolocumab-Reply. JAMA Cardiol. 2021 Oct 1;6(10):1222-1223.
Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. European Heart Journal – Digital Health, Volume 3, Issue 1, March 2022, Pages 38–48.